YTHDF2 and central nervous system cancer: Additionally, positive correlations between the expression of YTHDF2 and immune checkpoints, including PD-1, TIM-3 and CTLA-4, have been observed in lower-grade glioma (LGG), emphasizing a role for YTHDF2 as a novel prognostic biomarker [111].